Amalgamation/Merger

Emcure Ref: EPL/CS/SE/0088/2026 Date: October 12, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, P J Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400 051 Mumbai- 400 001 Script Symbol: EMCURE Scrip Code/Symbol: 544210/ EMCURE Dear Sir/Madam, Subject: Outcome of the Board Meeting held on October 12, 2026 - Scheme of Amalgamation of certain wholly owned subsidiaries with Emcure Pharmaceuticals Limited – Holding Company. In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “SEBI Listing Regulations”), we wish to inform you that the Board of Directors at its meeting held on Monday, October 12, 2026 has inter alia, approved the draft Composite Scheme of Amalgamation amongst Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited (collectively referred to as the “Transferor Companies") both being wholly owned subsidiaries of the Company with Emcure Pharmaceuticals Limited (hereinafter referred to as the “Company” or “Transferee Company”) and their respective shareholders and creditors pursuant to Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 (“Scheme”). The Scheme is subject to necessary statutory and regulatory approvals under applicable laws, including the approval of the Hon'ble National Company Law Tribunal, Mumbai Bench. The disclosure as required pursuant to Regulation 30 of the SEBI Listing Regulations read with the SEBI Circular HO/49/ 14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed herewith and marked as Annexure A. The meeting of the Board of Directors of the Company commenced at 09:45 a.m. (IST) and concluded at 10: 10 a.m. (IST). You are requested to take the above information on your records. Thanking you, For Emcure Pharmaceuticals Limited Amruta Yangalwar Company Secretary & Compliance Officer ICSI Membership No.: A25687 Encl: As above Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251 Emcure Annexure - A Disclosure Required under Regulation 30 of the SEBI Listing Regulations read with SEBl Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Sr. Particulars Details 1 Name of the entity(ies) Transferor Companies: forming part of the Zuventus Healthcare Limited amalgamation/merger, details Emcutix Biopharmaceuticals Limited in brief such as size, turnover, etc. Transferee Company: Emcure Pharmaceuticals Limited (INR in crores) Name of Company Networth as Turnover for on March 31, FY 2025-26 2026 Zuventus 871.46 1,040.58 Healthcare Limited Emcutix (13.07) 29.37 Biopharmaceuticals Limited Emcure 3,710.60 5,243.19 Pharmaceuticals Limited 2 Whether the transaction would The Scheme involves the amalgamation of wholly fall within related party owned subsidiary companies with the holding transactions? If yes, whether company. Therefore, it is exempted as per Regulation the same is done at “arm’s 23(5)(b) of the SEBI Listing Regulations. length” Furthermore, in accordance with the General Circular No. 30/2014 dated July 17, 2014, issued by the Ministry of Corporate Affairs, transactions resulting from compromises, arrangements, and amalgamations under the Companies Act 2013, are not subject to the requirements of Section 188 of Companies Act, 2013. 3 Area of business of the Pharmaceutical entity(ies) 4 Rationale for amalgamation/ To achieve entity rationalization and operational merger efficiency within the group. 5 In case of cash consideration – No consideration shall be payable. The entire share amount or otherwise share capital of Transferor Companies is held by the exchange ratio consideration Company and no shares shall be issued pursuant to the Scheme. 6 Brief details of change in There will be no change in the shareholding pattern of shareholding pattern (if any) of the Company pursuant to the aforesaid Scheme, as no the listed entity shares would be issued by the Company in consideration for the amalgamation. Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251